Prolaris added significantly to prediction of BCR in multivariate analysis, both in overall cohort and subset of men meeting NCCN low risk criteria.
“In a cohort of NCCN low-risk patients, the CCP score improved clinical risk stratification of patients at increased risk of BCR [biochemical recurrence], which suggests the CCP score could improve the assessment of candidacy for active surveillance and guide optimal treatment selection in these patients with otherwise similar clinical parameters.”
Tosoian JJ, Chappidi MR, Bishoff JT, et al. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU Int 2017; 120:808-14.
Learn More View Article